Skip to main content
. Author manuscript; available in PMC: 2021 Jan 22.
Published in final edited form as: Mutat Res. 2020 Jan 22;849:503144. doi: 10.1016/j.mrgentox.2020.503144

Table 1.

Inhibition of Top2 with Pre-treatment with Dexrazoxane and Frequency of Bioflavonoid-induced Translocations.

Scored GFP+ Events Average Frequency
Compound Dose −DEX +DEX −DEX +DEX
Untreated n/a 0 0, 2, 4 <0.007 × 10−6 0.20 × 10−6
Etoposide 50 μM 80, 92, 68, 97 23, 25, 26 8.43 × 10−6 2.47 × 10−6
Genistein 75 μM 15, 8, 14 11, 17, 19 1.23 × 10−6 1.57 × 10−6
Kaempferol 100 μM 6, 2, 3, 4 10, 18, 19 0.38 × 10−6 1.57 × 10−6
Myricetin 100 μM 1, 1, 2 1, 0, 0 0.13 × 10−6 0.03 × 10−6

The MAG translocation reporter cell line was treated with 200 μM dexrazoxane for 5 h before 1 h treatment with etoposide (50 μM), genistein (75 μM), kaempferol (100 μM) or myricetin (50 μM). Number of GFP+ colonies were counted after 5–7 days. Experiment was repeated in triplicate and compared to our previous reported data without dexrazoxane pre-treatment. The translocation frequency decreased with dexrazoxane pre-treatment for etoposide (p= 0.0006), increased for kaempferol (p= 0.0058) and remained statistically unchanged for untreated, genistein, and myricetin (p= 0.272, 0.363, and 0.101, respectively).